Anti-inflammatory Therapy for Recurrent In-stent Restenosis

PHASE4RecruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

October 29, 2026

Study Completion Date

October 29, 2027

Conditions
In-stent Restenosis
Interventions
DRUG

Colchicine

Add 0.5mg QD orally and start using it within 48 hours after intervention.

DRUG

Prednisone

0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.

DRUG

Aspirin

Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.

DRUG

P2Y12 Receptor Antagonist

Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.

DRUG

Lipid-lowering drug

Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.

Trial Locations (4)

10000

RECRUITING

Beijing Anzhen Hospital, Capital Medical University, Beijing

NOT_YET_RECRUITING

Beijing Friendship Hospital, Beijing

RECRUITING

Beijing Luhe Hospital, Beijing

Unknown

RECRUITING

Fuwai Hospital, Beijing

All Listed Sponsors
lead

Fu Wai Hospital, Beijing, China

OTHER